These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31988667)

  • 1. Biosimilar biological drugs in the treatment of inflammatory bowel diseases.
    Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G
    Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.
    Vernero M; Bezzio C; Ribaldone DG; Costa S; Scalvini D; Tribocco E; Manes G; Saibeni S
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
    D'Amico F; Peyrin-Biroulet L; Danese S
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892780
    [No Abstract]   [Full Text] [Related]  

  • 5. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus.
    D'Amico F; Solitano V; Magro F; Olivera PA; Halfvarson J; Rubin D; Dignass A; Al Awadhi S; Kobayashi T; Queiroz NSF; Calvo M; Kotze PG; Ghosh S; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37834994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
    Amiot A; Peyrin-Biroulet L
    Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
    Carrascosa JM; Jacobs I; Petersel D; Strohal R
    Dermatol Ther (Heidelb); 2018 Jun; 8(2):173-194. PubMed ID: 29549597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Biosimilars in Inflammatory Bowel Disease.
    Paramsothy S; Cleveland NK; Zmeter N; Rubin DT
    Gastroenterol Hepatol (N Y); 2016 Dec; 12(12):741-751. PubMed ID: 28035201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 May; ():1-7. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan.
    Moroi R; Kakuta Y; Nagai H; Shimoyama Y; Naito T; Shiga H; Kinouchi Y; Masamune A
    Inflamm Intest Dis; 2024; 9(1):29-39. PubMed ID: 38344420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A SPECIAL MEETING REVIEW EDITION: Highlights in Biosimilars From the World Congress of Gastroenterology at ACG 2017: Introduction: A Review of Selected Presentations From the World Congress of Gastroenterology at ACG 2017 • October 13-18, 2017 • Orlando, Florida
    Gastroenterol Hepatol (N Y); 2017 Dec; 13(12 Suppl 4):1-20. PubMed ID: 30042651
    [No Abstract]   [Full Text] [Related]  

  • 12. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
    Baumgart DC; Misery L; Naeyaert S; Taylor PC
    Front Pharmacol; 2019; 10():279. PubMed ID: 30983996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study.
    Young D; Cummings F; Latter S
    Eur J Hosp Pharm; 2022 Jul; 31(2):143-9. PubMed ID: 35853694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.
    Rezk MF; Pieper B
    Rheumatol Ther; 2017 Dec; 4(2):209-218. PubMed ID: 29032452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.
    Park SH; Park JC; Lukas M; Kolar M; Loftus EV
    Intest Res; 2020 Jan; 18(1):34-44. PubMed ID: 32013313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars engage in low levels of direct-to-physician marketing relative to reference biologics.
    Hyland MF; Carey CM
    Health Aff Sch; 2023 Dec; 1(6):qxad069. PubMed ID: 38756369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast].
    Cohen SB; Leach MZ
    Open Access Rheumatol; 2023; 15():207-212. PubMed ID: 37927492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus.
    Ardizzone S; Armuzzi A; Caprioli F; Castiglione F; Danese S; Daperno M; Fantini MC; Fries W; Principi MB; Savarino E; Gionchetti P
    Dig Liver Dis; 2024 Jan; 56(1):98-105. PubMed ID: 37741750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilarity. Do not confuse biosimilar and biocopy. Example of tenecteplase.
    Astier A; Abouqal R; Abid L; Aoudia Y; Ahid S
    Ann Pharm Fr; 2023 Nov; 81(6):942-949. PubMed ID: 37422254
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.